Next year, Novo Nordisk’s patents for semaglutide — the key ingredient in weight-loss drugs Ozempic and Wegovy — will expire in India. Indian pharmaceutical companies are already racing to develop generic versions.
Right now, these drugs cost anywhere between Rs 17,000 and Rs 26,000 per month. But generics could cost up to 90% less, according to some estimates.
That means many more people in India could soon have access to semaglutide. But should you actually take it?
In today’s episode of The Signal Daily, we break down how these drugs work, who they’re for, and why some people should avoid them.
The Core produces The Signal Daily. To check out the rest of our work, go to www.thecore.in.
The Core and The Signal Daily are ad supported and FREE for all readers and listeners. Write in to shiva@thecore.in for sponsorships and brand studio requirements.
Follow us on: Twitter | Instagram | Facebook | Linkedin
